tirzepatide ruling 2025 What The FDA's Changes Mean for Providers in September 2, 2025: U.S. compounding
Description
On October 2, 2024, the FDA declared the tirzepatide shortage resolved
According to the manufacturer's guidance and the Summary of Product Characteristics (SmPC) approved by the Medicines and Healthcare products Regulatory Agency (MHRA), tirzepatide pens may be kept at room temperature (not exceeding 30C) for up to 21 days
Will I see the same provider each time? 14
2025 Jan-
Biostimulators (Sculptra / Radiesse) For those with Mounjaro face, biostimulators are key
BMI 34-35: 12.5 mg
